GCM
BCYC

Graham Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Graham Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,375
Closed -$95.8K – 1232
2025
Q3 		$95.8K Sell
12,375
-727
-6% -$5.49K ﹤0.01% 1160
2025
Q2 		$91.1K Buy
+13,102
New +$104K ﹤0.01% 1214

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
GP
GSK plc London $599M AUM
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Graham Capital Management's BCYC Position: Q4 2025 in Review

Graham Capital Management sold out of Bicycle Therapeutics (BCYC) in Q4 2025, closing a stake of 12,375 shares — an estimated $95.8K sold.

Graham Capital Management first reported a position in BCYC in Q2 2025 and held it in 2 quarters. The position peaked at $95.8K in Q3 2025. 109 funds tracked by Wall St. Rank hold BCYC as of Q4 2025.

  • Graham Capital Management reported no remaining Bicycle Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 12,375 Bicycle Therapeutics shares in Q4 2025, an estimated $95.8K.
  • Graham Capital Management first reported a position in Bicycle Therapeutics in Q2 2025 and held it in 2 quarters.
  • Graham Capital Management's Bicycle Therapeutics position peaked at $95.8K in Q3 2025.
  • 109 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.